Diamond Hill Capital Management LLC Investment Advisor Buys Shares of 1,945,121 Solventum Corporation $SOLV

Diamond Hill Capital Management LLC Investment Advisor purchased a new stake in shares of Solventum Corporation (NYSE:SOLV - Free Report) during the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor purchased 1,945,121 shares of the company's stock, valued at approximately $150,066,000. Solventum makes up approximately 1.2% of Diamond Hill Capital Management LLC Investment Advisor's investment portfolio, making the stock its 28th biggest position. Diamond Hill Capital Management LLC Investment Advisor owned 1.12% of Solventum as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors also recently modified their holdings of the business. Independent Franchise Partners LLP raised its position in Solventum by 19.0% in the 4th quarter. Independent Franchise Partners LLP now owns 15,355,691 shares of the company's stock worth $1,216,785,000 after buying an additional 2,456,451 shares during the last quarter. Norges Bank bought a new position in Solventum during the 4th quarter valued at about $147,467,000. Diamond Hill Capital Management Inc. boosted its holdings in shares of Solventum by 152.2% during the 4th quarter. Diamond Hill Capital Management Inc. now owns 2,109,027 shares of the company's stock valued at $167,119,000 after acquiring an additional 1,272,921 shares during the last quarter. Boston Partners boosted its holdings in shares of Solventum by 26.1% during the 3rd quarter. Boston Partners now owns 4,630,300 shares of the company's stock valued at $338,006,000 after acquiring an additional 959,543 shares during the last quarter. Finally, Bank of New York Mellon Corp bought a new stake in shares of Solventum in the second quarter worth approximately $61,460,000.

Analyst Ratings Changes

Several research firms have recently weighed in on SOLV. BTIG Research boosted their price objective on shares of Solventum from $91.00 to $95.00 and gave the company a "buy" rating in a report on Thursday, August 6th. Mizuho set a $113.00 target price on shares of Solventum in a report on Thursday, August 6th. Stifel Nicolaus lifted their target price on shares of Solventum from $90.00 to $100.00 and gave the stock a "buy" rating in a research report on Thursday, August 6th. Wells Fargo & Company cut their target price on shares of Solventum from $83.00 to $70.00 and set an "equal weight" rating for the company in a research report on Wednesday, May 6th. Finally, Weiss Ratings upgraded shares of Solventum from a "hold (c)" rating to a "hold (c+)" rating in a research note on Friday, July 17th. Seven investment analysts have rated the stock with a Buy rating, five have given a Hold rating and one has assigned a Sell rating to the company's stock. According to MarketBeat, Solventum presently has a consensus rating of "Hold" and an average price target of $91.64.

Solventum Price Performance

NYSE SOLV opened at $88.53 on Monday. Solventum Corporation has a 52 week low of $62.38 and a 52 week high of $90.00. The firm has a market capitalization of $15.07 billion, a P/E ratio of 10.82, a PEG ratio of 1.14 and a beta of 0.60. The company has a quick ratio of 0.74, a current ratio of 1.02 and a debt-to-equity ratio of 1.00. The company has a 50-day moving average price of $80.11 and a 200-day moving average price of $74.64.

Solventum (NYSE:SOLV - Get Free Report) last posted its quarterly earnings data on Wednesday, August 5th. The company reported $2.55 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.91 by $0.64. The company had revenue of $2.21 billion for the quarter, compared to the consensus estimate of $2.15 billion. Solventum had a net margin of 17.26% and a return on equity of 25.09%. The firm's revenue was up 2.2% compared to the same quarter last year. During the same quarter last year, the firm posted $1.69 earnings per share. Solventum has set its FY 2026 guidance at 7.100-7.200 EPS. Equities research analysts anticipate that Solventum Corporation will post 7.22 earnings per share for the current year.

Solventum Company Profile

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration. The Medsurg segment is a provider of solutions including advanced wound care, I.V. site management, sterilization assurance, temperature management, surgical supplies, stethoscopes, and medical electrodes.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source